Kimia Biosciences Limited
BSE: KIMIABL · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Kimia Biosciences Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Kimia Biosciences Limited is an Indian pharmaceutical company specialising in the manufacturing of bulk drugs and active pharmaceutical ingredients (APIs). The firm focuses on therapeutic areas including oncology, lifestyle diseases, and central nervous system disorders.
Business Model
The company generates revenue by developing and supplying high-potential generic APIs and complex intermediates to pharmaceutical formulation manufacturers. It leverages advanced research, development, and synthetic chemistry capabilities at its Haryana-based manufacturing facility.
Growth Outlook
Growth is driven by the expansion of the product portfolio to include complex molecules and intermediates for the global healthcare industry. The company continues to enhance its manufacturing capabilities to meet international regulatory standards.
Key Risks
- Regulatory Compliance. Failure to maintain international regulatory standards at manufacturing facilities could restrict access to key global markets.
- R&D Execution. The company's growth depends on the successful development and commercialisation of complex molecules and generic APIs.
- Market Competition. The pharmaceutical API sector is highly competitive, potentially impacting pricing power and profit margins.
- Input Cost Volatility. Fluctuations in the cost of raw materials and chemical intermediates can adversely affect the company's operational profitability.
Start your research today
Unlock AI insights, financials, peers and live data on Kimia Biosciences Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹111 Cr
TTM · standalone
NET PROFIT
₹9 Cr
TTM · standalone
EPS
₹1.99
TTM · standalone
RETURN ON EQUITY
826.3%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
37.8%
TTM · standalone
P/E
16.6x
Q3 FY25 · standalone
EV/EBITDA
10.3x
Q3 FY25 · standalone
EBITDA MARGIN
15.7%
TTM · standalone
DEBT TO EQUITY
1.9x
Q4 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Kimia Biosciences LimitedKIMIABL | ₹132 Cr | — | — | 14.1% | 15.7% | 826.3% | 37.8% | -25.3% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Q3 FY25
Financials
Kimia Biosciences Limited
BSE: KIMIABL · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Kimia Biosciences Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Kimia Biosciences Limited is an Indian pharmaceutical company specialising in the manufacturing of bulk drugs and active pharmaceutical ingredients (APIs). The firm focuses on therapeutic areas including oncology, lifestyle diseases, and central nervous system disorders.
Business Model
The company generates revenue by developing and supplying high-potential generic APIs and complex intermediates to pharmaceutical formulation manufacturers. It leverages advanced research, development, and synthetic chemistry capabilities at its Haryana-based manufacturing facility.
Growth Outlook
Growth is driven by the expansion of the product portfolio to include complex molecules and intermediates for the global healthcare industry. The company continues to enhance its manufacturing capabilities to meet international regulatory standards.
Key Risks
- Regulatory Compliance. Failure to maintain international regulatory standards at manufacturing facilities could restrict access to key global markets.
- R&D Execution. The company's growth depends on the successful development and commercialisation of complex molecules and generic APIs.
- Market Competition. The pharmaceutical API sector is highly competitive, potentially impacting pricing power and profit margins.
- Input Cost Volatility. Fluctuations in the cost of raw materials and chemical intermediates can adversely affect the company's operational profitability.
Start your research today
Unlock AI insights, financials, peers and live data on Kimia Biosciences Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹111 Cr
TTM · standalone
NET PROFIT
₹9 Cr
TTM · standalone
EPS
₹1.99
TTM · standalone
RETURN ON EQUITY
826.3%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
37.8%
TTM · standalone
P/E
16.6x
Q3 FY25 · standalone
EV/EBITDA
10.3x
Q3 FY25 · standalone
EBITDA MARGIN
15.7%
TTM · standalone
DEBT TO EQUITY
1.9x
Q4 FY26 · standalone
Peers · Pharmaceuticals
As of Q3 FY25